Clinical experience with linezolid for the treatment of neurosurgical infections

摘要: for the treatment of neurosurgical infections. Retrospective observational study a cohort of hospitalized patients who received linezolid culture-positive neurosurgical infection from July 2004 to February 2009 in tertiary hospital in Spain. Seventeen were included study. Main comorbidities among these one or more of following: subarachnoidal intraventricular hemorrhage (n=8), solid neurological cancer (n=7), corticosteroids (n=9) and hydrocephalus (n=6). Eight underwent a craniotomy fourteen had an external ventricular drainage (EVD) as predisposing factors infection. Meningitis was most common (11; 64.7%), followed by ventriculitis (4; 23.5%) brain abscesses (2; 11.8%). The main causative organisms coagulase-negative Staphylococcus spp. (13; 76.5%). Linezolid used the initial therapy 8 episodes, after failure 6 for other reasons 3. oral route 9 (52.9%) episodes; linezolid initiated orally 2 cases. mean duration of 26.5 days (range 15-58). No adverse events were reported. Sixteen (94.1%) considered cured. There recurrence. length stay was 45.6 15-112) duration follow- up 7.2 0.4-32) months. related deaths occurred during active episodes. Linezolid mainly indicated post-neurosurgical EVD-associated infections due It initial most cases. A high rate clinical cure observed no related adverse events More than half benefited advantages administration